ESPR - Esperion Therapeutics Inc

Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.

52W High

$3.94

52W Low

$0.69

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.89

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

7.66

EV/EBITDA (<8 favorable)

48.73

EV/Revenue (<3 favorable)

2.82

P/S (TTM) (<3 favorable)

2.02

P/B (<3 favorable)

98.42

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.56%

Institutions (25–75% balanced)

50.56%

Shares Outstanding

201,623,000

Float

199,760,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

268,125,000

Gross Profit (TTM)

123,958,000

EPS (TTM)

-0.54

Profit Margin (>10% good)

-0.39%

Operating Margin (TTM) (higher better)

0.09%

ROE (TTM) (>15% strong)

-2.61%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.12

Momentum

Bearish momentum

Value

0.3121

0.2979

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025